ArticleBMC cancer2023

Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.

Chun-Ta Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.